156 related articles for article (PubMed ID: 25980633)
1. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
Juratli TA; Cahill DP; McCutcheon IE
Expert Rev Anticancer Ther; 2015 Jun; 15(6):603-6. PubMed ID: 25980633
[TBL] [Abstract][Full Text] [Related]
2. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
Bleeker FE; Atai NA; Lamba S; Jonker A; Rijkeboer D; Bosch KS; Tigchelaar W; Troost D; Vandertop WP; Bardelli A; Van Noorden CJ
Acta Neuropathol; 2010 Apr; 119(4):487-94. PubMed ID: 20127344
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
Liu S; Shah Z; Sav A; Russo C; Berkovsky S; Qian Y; Coiera E; Di Ieva A
Sci Rep; 2020 May; 10(1):7733. PubMed ID: 32382048
[TBL] [Abstract][Full Text] [Related]
4. Targeting IDH-Mutant Glioma.
Miller JJ
Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
[TBL] [Abstract][Full Text] [Related]
5. Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
Nassiri F; Ajisebutu A; Patil V; Mamatjan Y; Liu J; Wang JZ; Voisin MR; Nejad R; Mansouri S; Karimi S; Chakravarthy A; Chen E; De Carvalho DD; Aldape K; Zadeh G
Acta Neuropathol; 2024 Apr; 147(1):68. PubMed ID: 38583102
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
[TBL] [Abstract][Full Text] [Related]
7. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning.
Zheng S; Rammohan N; Sita T; Teo PT; Wu Y; Lesniak M; Sachdev S; Thomas TO
Sci Rep; 2024 Jan; 14(1):2126. PubMed ID: 38267516
[TBL] [Abstract][Full Text] [Related]
8. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract][Full Text] [Related]
9. Glutamate and α-ketoglutarate: key players in glioma metabolism.
Maus A; Peters GJ
Amino Acids; 2017 Jan; 49(1):21-32. PubMed ID: 27752843
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
Sharma N; Mallela AN; Shi DD; Tang LW; Abou-Al-Shaar H; Gersey ZC; Zhang X; McBrayer SK; Abdullah KG
Neurooncol Adv; 2023; 5(1):vdad053. PubMed ID: 37287696
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of Radiomics in Predicting
Di Salle G; Tumminello L; Laino ME; Shalaby S; Aghakhanyan G; Fanni SC; Febi M; Shortrede JE; Miccoli M; Faggioni L; Cosottini M; Neri E
Radiol Artif Intell; 2024 Jan; 6(1):e220257. PubMed ID: 38231039
[TBL] [Abstract][Full Text] [Related]
12. DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
Shi DD; Anand S; Abdullah KG; McBrayer SK
J Neurooncol; 2023 May; 162(3):515-523. PubMed ID: 36352183
[TBL] [Abstract][Full Text] [Related]
13. Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
Pu F; Alfaro CM; Pirro V; Xie Z; Ouyang Z; Cooks RG
Anal Bioanal Chem; 2019 Mar; 411(8):1503-1508. PubMed ID: 30710208
[TBL] [Abstract][Full Text] [Related]
14. Emerging targets for anticancer vaccination: IDH.
Platten M; Bunse L; Wick W
ESMO Open; 2021 Aug; 6(4):100214. PubMed ID: 34271312
[TBL] [Abstract][Full Text] [Related]
15. Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.
Svenjeby C; Carstam L; Werlenius K; Bontell TO; Rydén I; Jacobsson J; Dénes A; Jakola AS; Corell A
J Neurooncol; 2022 Dec; 160(3):535-543. PubMed ID: 36434487
[TBL] [Abstract][Full Text] [Related]
16. Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Sim HW; Lorrey S; Khasraw M
Curr Neurol Neurosci Rep; 2023 Jun; 23(6):263-276. PubMed ID: 37154886
[TBL] [Abstract][Full Text] [Related]
17. Cerebellar high-grade astrocytoma with IDH mutations in the elderly: A report of two cases.
Matsumura N; Ikota H; Yamazaki T; Nakata S; Nobusawa S; Hirato J; Yoshimoto Y; Yokoo H
Neuropathology; 2018 Apr; ():. PubMed ID: 29635724
[TBL] [Abstract][Full Text] [Related]
18.
Kayabolen A; Yilmaz E; Bagci-Onder T
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356864
[TBL] [Abstract][Full Text] [Related]
19. IDH inhibition in gliomas: from preclinical models to clinical trials.
Rudà R; Horbinski C; van den Bent M; Preusser M; Soffietti R
Nat Rev Neurol; 2024 May; ():. PubMed ID: 38760442
[TBL] [Abstract][Full Text] [Related]
20. Shedding Light on
Hollon TC; Orringer DA
Clin Cancer Res; 2018 Jun; 24(11):2467-2469. PubMed ID: 29440182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
